Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of micafungin versus caspofungin in invasive candidiasis or candidemia
2004-001491-39Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of micafungin in invasive candidiasis and candidemia (3 arms), sponsored by Astellas Pharma. Primary endpoint: Overall treatment success at end of IV therapy. Started Oct 2004; status: completed.
02
Drugs
micafungin
03
Conditions
invasive candidiasiscandidemia
Beyond the preview
Go deeper on 2004-001491-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001491-39.